Results 171 to 180 of about 579,513 (302)

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

VIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda, Tatsuya Watanabe, Satoshi Yuhara, John M. Kelly, Hirotsugu Kurobe, Toshiharu Shinoka   +5 more
wiley   +1 more source

Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.

The Lancet, 1988
M. Simoons, A. Betriu, J. Col, R. Essen, J. Lubsen, P. Michel, W. Rutsch, W. Schmidt, C. Théry, Alec Vahanian, G. Willems, A. Arnold, D. Bono, F. C. Dougherty, H. Lambertz, B. Meier, P. Raynaud, G. Sanz, P. Serruys, R. Uebis, F. Werf, D. Wood, M. Verstraete   +22 more
semanticscholar   +1 more source

Tissue Plasminogen Activator to Resolve Elevated Purge System Pressure in a Catheter-Based Ventricular Assist Device. [PDF]

JACC Case Rep
Khattak S, Shamkhani W, Maqableh GM, Al-Shatanawi A, Khan SQ.   +4 more
europepmc   +1 more source

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older‐Age Bipolar Disorder ISBD Task Forces

Bipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Background Cognitive impairment is common in bipolar disorder (BD), but the underlying pathophysiology remains unclear. This systematic review aimed to (1) summarize all literature describing relationships of biofluid biomarkers and cognition in BD and (2) identify which biofluid biomarkers correlate most consistently with cognition in BD ...
Alexandra J. M. Beunders, Sigfried N. T. M. Schouws, Andrew T. Olagunju, Vicent Balanzá‐Martínez, Nicole C. M. Korten, Ralph W. Kupka, Katherine E. Burdick, Andre F. Carvalho, Ariel G. Gildengers, Lars V. Kessing, Roger S. McIntyre, Paula V. Nunes, Ayal Schaffer, Ivan J. Torres, Shang‐Ying Tsai, Tamsyn E. Van Rheenen, Eduard Vieta, Lakshmi N. Yatham, Allan H. Young, Lisa T. Eyler, Kamilla W. Miskowiak, Annemiek Dols   +21 more
wiley   +1 more source

A Multicenter, Open-Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial. [PDF]

Pharmacotherapy
Stringer KA, Goldberg D, Chen S, Thrush P, Graham EM, Lubert A, Myers J, McLellan L, Flott T, Nasr S, Schumacher KR.   +10 more
europepmc   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, Volume 183, Issue 15, Page 4111-4125, August 2026.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator

Stroke, 2012
B. Menon, J. Saver, S. Prabhakaran, M. Reeves, L. Liang, Daiwai M. Olson, E. Peterson, Adrian F. Hernandez, G. Fonarow, L. Schwamm, Eric E. Smith   +10 more
semanticscholar   +1 more source

Imaging efficacy and safety of low dose intraventricular tissue plasminogen activator in aneurysmal subarachnoid hemorrhage: case series. [PDF]

Acta Neurochir (Wien)
Liu C, Wroe WW, Zeineddine HA, Dawes B, Giordano M, McCabe A, Chen CJ, McBride DW, Gusdon AM, Choi HA, Blackburn SL.   +10 more
europepmc   +1 more source

Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Epidemiological evidence shows that obesity increases the risk of developing metabolic diseases. Nevertheless, the mechanisms behind this connection remain underappreciated. The substantial impact of these disorders on global health has led to extensive research efforts aimed at identifying the pathophysiological links between them.
Ghadeer Alhamar, Joanna Razafiarison, Fawaz Alzaid, Fahd Al‐Mulla, Rasheed Ahmad   +4 more
wiley   +1 more source

Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.

New England Journal of Medicine, 2011
B. Hemmelgarn, L. Moist, C. Lok, M. Tonelli, B. Manns, R. Holden, M. Leblanc, P. Faris, P. Barré, Jianguo Zhang, N. Scott-Douglas   +10 more
semanticscholar   +1 more source